Evidence map›Paper›PMID 31984598›Full record

Trial reportDiabetes, obesity & metabolism2020

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 15 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 15 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025 · on this map
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Dose-response effects on HbADiabetologia · 2024
    Trial
  18. Trial
  19. Trial
  20. Trial

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Juan Pablo FriasNational Research Institute, Los Angeles California, United States.ORCID 0000-0001-9486-1255
Michael A NauckDiabetes Center Bochum-Hattingen, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.ORCID 0000-0002-5749-6954
Joanna VanDiabetes Research Center, Tustin, California.
Charles BensonEli Lilly and Company, Indianapolis, Indiana.
Ross BrayEli Lilly and Company, Indianapolis, Indiana.
Xuewei CuiEli Lilly and Company, Indianapolis, Indiana.
Zvonko MilicevicEli Lilly and Company, Vienna, Austria.ORCID 0000-0002-6746-901X
Shweta UrvaEli Lilly and Company, Indianapolis, Indiana.
Axel HauptEli Lilly and Company, Indianapolis, Indiana.ORCID 0000-0003-4502-0470
Deborah A RobinsEli Lilly and Company, Indianapolis, Indiana.ORCID 0000-0001-9694-7319
Eli Lilly (United States) · USDiabetes Care Center · USNational Research Institute · USSt. Josef-Hospital · DE

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

aimTo assess the efficacy and tolerability of tirzepatide treatment using three different dose-escalation regimens in patients with type 2 diabetes. MATERIALS AND

methodsIn this double-blind, placebo-controlled study, patients were randomized (1:1:1:1) to receive either once-weekly subcutaneous tirzepatide or placebo. The tirzepatide dose groups and dose-escalation regimens were: 12 mg (4 mg weeks 0-3; 8 mg weeks 4-7; 12 mg weeks 8-11), 15 mg-1 (2.5 mg weeks 0-1; 5 mg weeks 2-3; 10 mg weeks 4-7; 15 mg weeks 8-11) and 15 mg-2 (2.5 mg weeks 0-3; 7.5 mg weeks 4-7; 15 mg weeks 8-11). The primary objective was to compare tirzepatide with placebo in HbA1c change from baseline at 12 weeks.

resultsOverall, 111 patients were randomized: placebo, 26; tirzepatide 12 mg, 29; tirzepatide 15 mg-1, 28; tirzepatide 15 mg-2, 28. The mean age was 57.4 years, HbA1c 8.4% and body mass index 31.9 kg/m

conclusionsTirzepatide treatment for 12 weeks resulted in clinically significant reductions in HbA1c. This suggests that lower starting doses and smaller dose increments are associated with a more favourable side effect profile.

Indexed as

Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideHypoglycemic AgentsAgedDouble-Blind MethodGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesGlycated HemoglobinHumansMaleMiddle AgedTirzepatideTreatment OutcomeGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsTirzepatideantidiabetic drugglucagon-like peptide-1 analogueglucose-dependent insulinotropic peptideincretin therapyrandomized trialtype 2 diabetes

Identifiers

PMID31984598
PMCPMC7318331
OpenAlexW3004172664

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.